Although demonstrating better clinical efficacy than conventional chemotherapies (7, 8), these BRAF and MEK inhibitors engender inevitable drug resistance caused by complex mechanisms, which eventually lead to tumor cell proliferation and poor prognosis of melanoma patients (9–11). This evidence concerns the gene BRAF and melanoma.